MA54512A - Dérivés de la quinoléine destinés à une utilisation dans le traitement ou la prévention du cancer - Google Patents
Dérivés de la quinoléine destinés à une utilisation dans le traitement ou la prévention du cancerInfo
- Publication number
- MA54512A MA54512A MA054512A MA54512A MA54512A MA 54512 A MA54512 A MA 54512A MA 054512 A MA054512 A MA 054512A MA 54512 A MA54512 A MA 54512A MA 54512 A MA54512 A MA 54512A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- prevention
- treatment
- quinoline derivatives
- quinoline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306783.4A EP3669874A1 (fr) | 2018-12-20 | 2018-12-20 | Dérivés de la quinoline destinés à être utilisés dans le traitement ou la prévention du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54512A true MA54512A (fr) | 2021-10-27 |
Family
ID=65200518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054512A MA54512A (fr) | 2018-12-20 | 2019-12-19 | Dérivés de la quinoléine destinés à une utilisation dans le traitement ou la prévention du cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220071985A1 (fr) |
| EP (2) | EP3669874A1 (fr) |
| JP (1) | JP7570641B2 (fr) |
| KR (2) | KR20210136969A (fr) |
| CN (2) | CN113543784A (fr) |
| AU (1) | AU2019408244B2 (fr) |
| BR (1) | BR112021012132A2 (fr) |
| IL (1) | IL284124B2 (fr) |
| MA (1) | MA54512A (fr) |
| MX (1) | MX2021007178A (fr) |
| WO (1) | WO2020127839A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023126951A1 (fr) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibiteurs d'interactions protéine-protéine liées à l'autophagie |
| WO2024109936A1 (fr) * | 2022-11-25 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | Forme cristalline de composé de quinoléine amine et son procédé de préparation |
| WO2025027388A1 (fr) | 2023-08-01 | 2025-02-06 | Abivax | Obéfazimod pour le traitement de la rectocolite hémorragique |
| CN121532389A (zh) * | 2023-08-30 | 2026-02-13 | 江苏正大丰海制药有限公司 | 用于调节微小rna-124活性的化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201910781T4 (tr) | 2009-06-12 | 2019-08-21 | Abivax | Kanser tedavisi için yararlı bileşikler. |
| EP2465502A1 (fr) | 2010-12-15 | 2012-06-20 | Société Splicos | Composés utiles pour traiter le SIDA |
| EP2757161A1 (fr) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 comme biomarqueur de l'infection virale |
| CN103787992B (zh) * | 2014-01-21 | 2016-04-20 | 华东理工大学 | N,n-双取代苯并氮杂环-2-胺类化合物及其用途 |
| EP2975034A1 (fr) | 2014-07-17 | 2016-01-20 | Abivax | Dérivé de quinoléine pour le traitement de maladies inflammatoires et du sida |
| EP2974729A1 (fr) * | 2014-07-17 | 2016-01-20 | Abivax | Dérivés de quinoléine utilisés dans le traitement de maladies inflammatoires |
| EP3059236A1 (fr) * | 2015-02-23 | 2016-08-24 | Abivax | Nouveau dérivé de quinoléine pour utilisation dans le traitement et la prévention d'infections virales |
| JP6474334B2 (ja) * | 2015-07-30 | 2019-02-27 | 株式会社キーエンス | 画像検査装置、画像検査方法および画像検査プログラム |
| US10464903B2 (en) * | 2016-03-18 | 2019-11-05 | Ratiopharm Gmbh | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
-
2018
- 2018-12-20 EP EP18306783.4A patent/EP3669874A1/fr not_active Withdrawn
-
2019
- 2019-12-19 CN CN201980088810.8A patent/CN113543784A/zh active Pending
- 2019-12-19 EP EP19829187.4A patent/EP3897639A1/fr active Pending
- 2019-12-19 KR KR1020217022546A patent/KR20210136969A/ko not_active Ceased
- 2019-12-19 AU AU2019408244A patent/AU2019408244B2/en active Active
- 2019-12-19 MA MA054512A patent/MA54512A/fr unknown
- 2019-12-19 KR KR1020257024660A patent/KR20250117703A/ko active Pending
- 2019-12-19 BR BR112021012132-3A patent/BR112021012132A2/pt unknown
- 2019-12-19 US US17/416,679 patent/US20220071985A1/en active Pending
- 2019-12-19 WO PCT/EP2019/086470 patent/WO2020127839A1/fr not_active Ceased
- 2019-12-19 IL IL284124A patent/IL284124B2/en unknown
- 2019-12-19 MX MX2021007178A patent/MX2021007178A/es unknown
- 2019-12-19 JP JP2021535249A patent/JP7570641B2/ja active Active
- 2019-12-19 CN CN202411117196.2A patent/CN118986981A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL284124A (en) | 2021-08-31 |
| IL284124B2 (en) | 2025-07-01 |
| US20220071985A1 (en) | 2022-03-10 |
| JP7570641B2 (ja) | 2024-10-22 |
| AU2019408244B2 (en) | 2025-03-20 |
| CA3122912A1 (fr) | 2020-06-25 |
| MX2021007178A (es) | 2021-07-07 |
| CN113543784A (zh) | 2021-10-22 |
| CN118986981A (zh) | 2024-11-22 |
| WO2020127839A1 (fr) | 2020-06-25 |
| KR20210136969A (ko) | 2021-11-17 |
| KR20250117703A (ko) | 2025-08-05 |
| EP3897639A1 (fr) | 2021-10-27 |
| AU2019408244A1 (en) | 2021-07-08 |
| IL284124B1 (en) | 2025-03-01 |
| JP2022513517A (ja) | 2022-02-08 |
| EP3669874A1 (fr) | 2020-06-24 |
| BR112021012132A2 (pt) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3455205A4 (fr) | Peptidomimétiques pour le traitement d'une infection à norovirus | |
| EP3600281A4 (fr) | Traitement d'association pour le traitement ou la prévention de tumeurs | |
| EP3781564C0 (fr) | Dérivés de pyridazine pour le traitement du cancer | |
| MA49760A (fr) | Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique | |
| EP3533466A4 (fr) | Composition pharmaceutique pour le traitement et/ou la prévention du cancer | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
| MA54512A (fr) | Dérivés de la quinoléine destinés à une utilisation dans le traitement ou la prévention du cancer | |
| MA44020B1 (fr) | Composés antitumoraux | |
| EP3405183A4 (fr) | Dérivés d'adamatane pour le traitement d'une infection à filovirus | |
| MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
| EP3317274A4 (fr) | Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux | |
| EP3419981A4 (fr) | Polythérapies utilisées dans le traitement de l'amyotrophie spinale | |
| EP3813870C0 (fr) | Inhibiteur de ccr5 destiné à être utilisé dans le traitement du cancer | |
| EP3805216A4 (fr) | Composés pour le traitement ou la prévention de maladies hépatiques | |
| EP3471722A4 (fr) | Composés et méthodes pour la prévention et/ou le traitement du cancer | |
| EP3313818A4 (fr) | Procédés pour le traitement du sarcome de kaposi ou le lymphome induit par le kshv à l'aide de composés immunomodulateurs et utilisations de biomarqueurs | |
| MA47111A (fr) | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer | |
| EP3632431A4 (fr) | Agent de prévention ou de traitement de l'atrophie cérébrale | |
| MA51613A (fr) | Polythérapie pour le traitement ou la prévention du cancer | |
| MA51821A (fr) | Inhibiteurs de la thiorédoxine réductase à utiliser dans le traitement du cancer | |
| EP3636261A4 (fr) | Agent pour prévenir ou traiter une tauopathie | |
| EP3632430A4 (fr) | Agent de prévention ou de traitement de l'ataxie spinocérébelleuse | |
| EP3533471A4 (fr) | Composition pour le soulagement ou le traitement de la douleur | |
| EP3400025A4 (fr) | Utilisation de gaïacol pour la prévention et le traitement de glycogénoses |